{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:18:34Z","timestamp":1792783114890,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T00:00:00Z","timestamp":1690588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T00:00:00Z","timestamp":1690588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Schleswig-Holstein - Campus L\u00fcbeck","id":[{"id":"https:\/\/ror.org\/01tvm6f46","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The exact incidence and predictors of new-onset atrial fibrillation (AF) after percutaneous closure of patent foramen ovale (PFO) are unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We sought to find post-procedural AF incidence rates and differences due to different screening strategies and devices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search was conducted in Cochrane, MEDLINE and EMBASE. Controlled trials fulfilling the inclusion criteria were included into this meta-analysis. The incidence of new-onset AF was the primary outcome. Further parameters were surveillance strategy, device type, AF treatment and neurological events. New AF was determined as early onset within one month after implantation and late thereafter.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      8 controlled trials and 16 cohort studies were eligible for quantitative analysis. 7643 patients received percutaneous PFO closure after cryptogenic stroke or transient ischaemic attack, 117 with other indications, whereas 1792 patients formed the control group. Meta-analysis of controlled trials showed an AF incidence of 5.1% in the interventional and 1.6% in the conservative arm, respectively (OR 3.17, 95% CI 1.46\u20136.86,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.03,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200955%). 4.7% received high-quality surveillance strategy with Holter-ECG or Loop recorder whereby AF incidence was overall higher compared to the low-quality group with 12-lead ECG only (3.3\u201315% vs. 0.2\u20134.3%). Heterogeneous results on time of AF onset were found, limited by different follow-up strategies. CardioSEAL and Starflex seemed to have higher AF incidences in early and late onset with 4.5% and 4.2%, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Percutaneous PFO closure led to higher AF post-procedural incidence compared to the conservative strategy. Heterogeneity in surveillance and follow-up strategy limited the generalizability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>Registered on PROSPERO (CRD42022359945).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00392-023-02263-8","type":"journal-article","created":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T06:01:56Z","timestamp":1690610516000},"page":"1824-1834","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["New-onset atrial fibrillation after percutaneous patent foramen ovale closure: a meta-analysis"],"prefix":"10.1007","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7440-4986","authenticated-orcid":false,"given":"Dominik","family":"Jurczyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7080-6611","authenticated-orcid":false,"given":"Sascha","family":"Macherey-Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Rawish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Stiermaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Eitel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Frerker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,29]]},"reference":[{"issue":"6","key":"2263_CR1","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1161\/01.CIR.86.6.1902","volume":"86","author":"ND Bridges","year":"1992","unstructured":"Bridges ND, Hellenbrand W, Latson L, Filiano J, Newburger JW, Lock JE (1992) Transcatheter closure of patent foramen ovale after presumed paradoxical embolism. Circulation 86(6):1902\u20131908","journal-title":"Circulation"},{"issue":"13","key":"2263_CR2","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.4244\/EIJ-D-18-00622","volume":"14","author":"C Pristipino","year":"2019","unstructured":"Pristipino C, Horst S, Fabrizio DA et al (2019) European position paper on the management of patients with patent foramen ovaleGeneral approach and left circulation thromboembolism. EuroIntervention 14(13):1389\u20131402","journal-title":"EuroIntervention"},{"issue":"11","key":"2263_CR3","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1056\/NEJMoa1009639","volume":"366","author":"AJ Furlan","year":"2012","unstructured":"Furlan AJ, Reisman M, Massaro J et al (2012) Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med 366(11):991\u2013999","journal-title":"N Engl J Med"},{"issue":"12","key":"2263_CR4","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1056\/NEJMoa1211716","volume":"368","author":"B Meier","year":"2013","unstructured":"Meier B, Kalesan B, Mattle HP et al (2013) Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med 368(12):1083\u20131091","journal-title":"N Engl J Med"},{"issue":"6","key":"2263_CR5","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/ccd.22172","volume":"74","author":"S Staubach","year":"2009","unstructured":"Staubach S, Steinberg DH, Zimmermann W et al (2009) New onset atrial fibrillation after patent foramen ovale closure. Catheter Cardiovasc Interv 74(6):889\u2013895","journal-title":"Catheter Cardiovasc Interv"},{"issue":"8","key":"2263_CR6","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00392-010-0149-3","volume":"99","author":"P Wagdi","year":"2010","unstructured":"Wagdi P (2010) Incidence and predictors of atrial fibrillation following transcatheter closure of interatrial septal communications using contemporary devices. Clin Res Cardiol 99(8):507\u2013510","journal-title":"Clin Res Cardiol"},{"issue":"1","key":"2263_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1747-4949.2009.00336.x","volume":"5","author":"RF Bonvini","year":"2010","unstructured":"Bonvini RF, Sztajzel R, Dorsaz PA et al (2010) Incidence of atrial fibrillation after percutaneous closure of patent foramen ovale and small atrial septal defects in patients presenting with cryptogenic stroke. Int J Stroke 5(1):4\u20139","journal-title":"Int J Stroke"},{"issue":"2","key":"2263_CR8","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.carrev.2016.10.008","volume":"18","author":"G Rigatelli","year":"2017","unstructured":"Rigatelli G, Zuin M, Pedon L et al (2017) Clinically apparent long-term electric disturbances in the acute and very long-term of patent foramen ovale device-based closure. Cardiovasc Revasc Med 18(2):118\u2013122","journal-title":"Cardiovasc Revasc Med"},{"issue":"8","key":"2263_CR9","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1016\/j.ultrasmedbio.2019.04.015","volume":"45","author":"A Vitarelli","year":"2019","unstructured":"Vitarelli A (2019) Patent foramen ovale: pivotal role of transesophageal echocardiography in the indications for closure, assessment of varying anatomies and post-procedure follow-up. Ultrasound Med Biol 45(8):1882\u20131895","journal-title":"Ultrasound Med Biol"},{"key":"2263_CR10","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/ccd.30019","volume":"99","author":"A Andersen","year":"2021","unstructured":"Andersen A, Matzen KL, Andersen G et al (2021) Atrial fibrillation after closure of patent foramen ovale in the REDUCE clinical study. Catheter Cardiovasc Interv 99:1551\u20131557","journal-title":"Catheter Cardiovasc Interv"},{"key":"2263_CR11","doi-asserted-by":"publisher","first-page":"100919","DOI":"10.1016\/j.ijcha.2021.100919","volume":"37","author":"F Leclercq","year":"2021","unstructured":"Leclercq F, Odorico X, Marin G et al (2021) Atrial fibrillation screening on systematic ambulatory electrocardiogram monitoring after percutaneous patent foramen ovale closure: a prospective study. IJC Heart Vasc 37:100919","journal-title":"IJC Heart Vasc"},{"issue":"17","key":"2263_CR12","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.4244\/EIJ-D-18-00767","volume":"14","author":"AY Elgendy","year":"2019","unstructured":"Elgendy AY, Islam YE, Mohammad KM et al (2019) New-onset atrial fibrillation following percutaneous patent foramen ovale closure: a systematic review and meta-analysis of randomised trials. EuroIntervention 14(17):1788\u20131790","journal-title":"EuroIntervention"},{"issue":"2","key":"2263_CR13","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s10840-020-00925-5","volume":"60","author":"L Oliva","year":"2021","unstructured":"Oliva L, Huszti E, Barker M et al (2021) New-onset atrial fibrillation following percutaneous closure of patent foramen ovale: a systematic review and meta-analysis. J Interv Card Electrophysiol 60(2):165\u2013174","journal-title":"J Interv Card Electrophysiol"},{"issue":"5","key":"2263_CR14","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s00392-021-01964-2","volume":"111","author":"D Vukadinovi\u0107","year":"2022","unstructured":"Vukadinovi\u0107 D, Scheller B, Ukena C, Ewen S, Mahfoud F, B\u00f6hm M (2022) Device-related risk of atrial fibrillation after closure of patent foramen ovale: a systematic review and meta-analysis. Clin Res Cardiol 111(5):583\u2013587","journal-title":"Clin Res Cardiol"},{"key":"2263_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535","journal-title":"BMJ"},{"key":"2263_CR16","volume-title":"The 2011 Oxford CEBM evidence levels of evidence (Introductory Document)","author":"J Howick","year":"2011","unstructured":"Howick J, Chalmers I, Glasziou P et al (2011) The 2011 Oxford CEBM evidence levels of evidence (Introductory Document). Oxford Centre for Evidence-Based Medicine"},{"key":"2263_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928","journal-title":"BMJ"},{"key":"2263_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919","journal-title":"BMJ"},{"issue":"1","key":"2263_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000113427","volume":"111","author":"A Burow","year":"2008","unstructured":"Burow A, Schwerzmann M, Wallmann D et al (2008) Atrial fibrillation following device closure of patent foramen ovale. Cardiology 111(1):47\u201350","journal-title":"Cardiology"},{"issue":"11","key":"2263_CR20","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1610057","volume":"377","author":"JL Saver","year":"2017","unstructured":"Saver JL, Carroll JD, Thaler DE et al. (2017) Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke. N Engl J Med 2017; 377:1022\u20131032","journal-title":"N Engl J Med"},{"issue":"20","key":"2263_CR21","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/j.jacc.2018.02.046","volume":"71","author":"PH Lee","year":"2018","unstructured":"Lee PH, Song JK, Kim JS et al (2018) Cryptogenic stroke and high-risk patent foramen ovale: the DEFENSE-PFO trial. J Am Coll Cardiol 71(20):2335\u20132342","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"2263_CR22","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1705915","volume":"377","author":"JL Mas","year":"2017","unstructured":"Mas JL, Derumeaux G, Guillon B et al (2017) Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med 377(11):1011\u20131021","journal-title":"N Engl J Med"},{"issue":"1","key":"2263_CR23","doi-asserted-by":"publisher","first-page":"38","DOI":"10.5543\/tkda.2015.68148","volume":"43","author":"AH Ate\u015f","year":"2015","unstructured":"Ate\u015f AH, Sunman H, Aytemir K et al (2015) Prevention of recurrent cryptogenic stroke with percutaneous closure of patent foramen ovale; one year follow-up study with magnetic resonance imaging and Holter monitoring. Turk Kardiyoloji Dernegi Arsivi 43(1):38\u201346","journal-title":"Turk Kardiyoloji Dernegi Arsivi"},{"issue":"8","key":"2263_CR24","first-page":"365","volume":"18","author":"J Alaeddini","year":"2006","unstructured":"Alaeddini J, Feghali G, Jenkins S, Ramee S, White C, Abi-Samra F (2006) Frequency of atrial tachyarrhythmias following transcatheter closure of patent foramen ovale. J Invasive Cardiol 18(8):365\u2013368","journal-title":"J Invasive Cardiol"},{"issue":"1","key":"2263_CR25","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/ccd.20722","volume":"68","author":"FM Kiblawi","year":"2006","unstructured":"Kiblawi FM, Sommer RJ, Levchuck SG (2006) Transcatheter closure of patent foramen ovale in older adults. Catheter Cardiovasc Interv 68(1):136\u2013142","journal-title":"Catheter Cardiovasc Interv"},{"issue":"1","key":"2263_CR26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ijcard.2009.05.035","volume":"146","author":"G Bronzetti","year":"2011","unstructured":"Bronzetti G, D\u2019Angelo C, Donti A et al (2011) Role of atrial fibrillation after transcatheter closure of patent foramen ovale in patients with or without cryptogenic stroke. Int J Cardiol 146(1):17\u201321","journal-title":"Int J Cardiol"},{"issue":"43","key":"2263_CR27","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.1093\/eurheartj\/eht283","volume":"34","author":"M Hornung","year":"2013","unstructured":"Hornung M, Bertog SC, Franke J et al (2013) Long-termresults of a randomized trial comparing three different devices for percutaneous closure of a patent foramen ovale. Eur Heart J 34(43):3362\u20133369","journal-title":"Eur Heart J"},{"issue":"4","key":"2263_CR28","doi-asserted-by":"publisher","first-page":"244","DOI":"10.14503\/THIJ-17-6582","volume":"47","author":"L He","year":"2020","unstructured":"He L, Cheng G, Du Y, Zhang Y (2020) Importance of persistent right-to-left shunt after patent foramen ovale closure in cryptogenic stroke patients. Tex Heart Inst J 47(4):244\u2013249","journal-title":"Tex Heart Inst J"},{"issue":"2","key":"2263_CR29","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/joic.12181","volume":"28","author":"NA Geis","year":"2015","unstructured":"Geis NA, Pleger ST, Katus HA, Hardt SE (2015) Using the GORE\u00ae septal occluder (GSO) in challenging patent foramen ovale (PFO) anatomies. J Interv Cardiol 28(2):190\u2013197","journal-title":"J Interv Cardiol"},{"issue":"2","key":"2263_CR30","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/ccd.23119","volume":"79","author":"J Kefer","year":"2012","unstructured":"Kefer J, Sluysmans T, Hermans C et al (2012) Percutaneous transcatheter closure of interatrial septal defect in adults: procedural outcome and long-term results. Catheter Cardiovasc Interv 79(2):322\u2013330","journal-title":"Catheter Cardiovasc Interv"},{"issue":"6","key":"2263_CR31","doi-asserted-by":"publisher","first-page":"717","DOI":"10.4244\/EIJV8I6A111","volume":"8","author":"C Heinisch","year":"2012","unstructured":"Heinisch C, Bertog S, Wunderlich N et al (2012) Percutaneous closure of the patent foramen ovale using the HELEX\u00ae septal occluder: acute and long-term results in 405 patients. EuroIntervention 8(6):717\u2013723","journal-title":"EuroIntervention"},{"issue":"3","key":"2263_CR32","doi-asserted-by":"publisher","first-page":"345","DOI":"10.4244\/EIJV8I3A53","volume":"8","author":"LJ Stanczak","year":"2012","unstructured":"Stanczak LJ, Bertog SC, Wunderlich N, Franke J, Sievert H (2012) PFO closure with the Premere PFO closure device: acute results and follow-up of 263 patients. EuroIntervention 8(3):345\u2013351","journal-title":"EuroIntervention"},{"issue":"3","key":"2263_CR33","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/ccd.26053","volume":"87","author":"P Scacciatella","year":"2016","unstructured":"Scacciatella P, Meynet I, Presbitero P et al (2016) Recurrent cerebral ischemia after patent foramen ovale percutaneous closure in older patients: a two-center registry study. Catheter Cardiovasc Interv 87(3):508\u2013514","journal-title":"Catheter Cardiovasc Interv"},{"issue":"6","key":"2263_CR34","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/echo.13842","volume":"35","author":"P Scacciatella","year":"2018","unstructured":"Scacciatella P, Meynet I, Giorgi M et al (2018) Angiography vs transesophageal echocardiography-guided patent foramen ovale closure: a propensity score matched analysis of a two-center registry. Echocardiography 35(6):834\u2013840","journal-title":"Echocardiography"},{"issue":"22","key":"2263_CR35","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1016\/j.jcin.2022.07.044","volume":"15","author":"P Guedeney","year":"2022","unstructured":"Guedeney P, Laredo M, Zeitouni M et al (2022) Supraventricular arrhythmia following patent foramen ovale percutaneous closure. J Am Coll Cardiol Intv 15(22):2315\u20132322","journal-title":"J Am Coll Cardiol Intv"},{"issue":"3","key":"2263_CR36","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/ccd.28766","volume":"95","author":"H Won","year":"2020","unstructured":"Won H, Carroll JD (2020) Comparative effectiveness research applied to medical devices: Which PFO closure device is the best? Catheter Cardiovasc Interv 95(3):373\u2013374","journal-title":"Catheter Cardiovasc Interv"},{"issue":"13","key":"2263_CR37","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.021045","volume":"10","author":"ID Kotadia","year":"2021","unstructured":"Kotadia ID, Sim I, Mukherjee R et al (2021) Secondary stroke prevention following embolic stroke of unknown source in the absence of documented atrial fibrillation: a clinical review. J Am Heart Assoc 10(13):e021045","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"2263_CR38","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa1105575","volume":"366","author":"JS Healey","year":"2012","unstructured":"Healey JS, Connolly SJ, Gold MR et al (2012) Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 366(2):120\u2013129","journal-title":"N Engl J Med"},{"issue":"20","key":"2263_CR39","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1056\/NEJMoa011258","volume":"345","author":"JP Mohr","year":"2001","unstructured":"Mohr JP, Thompson JLP, Lazar RM et al (2001) A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 345(20):1444\u20131451","journal-title":"N Engl J Med"},{"issue":"23","key":"2263_CR40","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1056\/NEJMoa1802686","volume":"378","author":"RG Hart","year":"2018","unstructured":"Hart RG, Sharma M, Mundl H et al (2018) Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 378(23):2191\u20132201","journal-title":"N Engl J Med"},{"issue":"20","key":"2263_CR41","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1056\/NEJMoa1813959","volume":"380","author":"H-C Diener","year":"2019","unstructured":"Diener H-C, Sacco RL, Easton JD et al (2019) Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med 380(20):1906\u20131917","journal-title":"N Engl J Med"},{"key":"2263_CR42","first-page":"23","volume":"8","author":"T Geisler","year":"2022","unstructured":"Geisler T, Keller T, Martus P, Ziemann U, Poli S (2022) Neue Daten zum embolischen Schlaganfall unbekannter Ursache. CardioNews 8:23","journal-title":"CardioNews"},{"issue":"10310","key":"2263_CR43","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/S0140-6736(21)01637-8","volume":"398","author":"E Svennberg","year":"2021","unstructured":"Svennberg E, Friberg L, Frykman V, Al-Khalili F, Engdahl J, Rosenqvist M (2021) Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial. Lancet 398(10310):1498\u20131506","journal-title":"Lancet"},{"issue":"10310","key":"2263_CR44","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/S0140-6736(21)01698-6","volume":"398","author":"JH Svendsen","year":"2021","unstructured":"Svendsen JH, Diederichsen SZ, H\u00f8jberg S et al (2021) Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial. Lancet 398(10310):1507\u20131516","journal-title":"Lancet"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-023-02263-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-023-02263-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-023-02263-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T11:57:39Z","timestamp":1701777459000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-023-02263-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,29]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["2263"],"URL":"https:\/\/doi.org\/10.1007\/s00392-023-02263-8","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,29]]},"assertion":[{"value":"26 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DJ: None. SMM: None. ER: None. TS: None. IE: None. CF: None. TS: None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}